Related Experiment Videos
[Radioprogestins. Their clinical use]
1Depto. de Fisiología, Fac. Medicina, UNAM, México, D.F.
Ginecologia Y Obstetricia De Mexico
|October 1, 1994
Summary
A novel radioprogestin labeled with iodine-131 shows promise for diagnosing and treating progesterone receptor-positive meningiomas. Early results in patients indicate good tumor localization and treatment response with no observed toxicity.
Area of Science:
- Nuclear medicine
- Oncology
- Radiopharmacology
Background:
- Meningiomas are common primary brain tumors, often hormone-dependent.
- Effective diagnostic and therapeutic agents for meningiomas are needed.
Purpose of the Study:
- To synthesize and evaluate a novel radioprogestin (iodine-131 labeled) for meningioma diagnosis and treatment.
- To assess the safety and efficacy of this radioprogestin in patients with hormone-dependent meningiomas.
Main Methods:
- Synthesis of a radioprogestin labeled with iodine-131.
- Administration of the radioprogestin to patients with meningioma for diagnostic imaging.
- Treatment of one patient with the radioprogestin.
Main Results:
- Successful synthesis of the radioprogestin.
- Very good results in the scan for cerebral tumor localization in two patients.
- Positive treatment response in one patient.
- No radiotoxicity or intolerance observed during six months of follow-up.
Conclusions:
- The novel radioprogestin is a promising new radiopharmaceutical for the diagnosis and treatment of progesterone receptor-positive meningiomas.
- Further investigation is warranted to establish its role in clinical practice.